Related Experiment Video
Updated: Jun 28, 2026
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
The type 1 insulin-like growth factor receptor pathway
Meenali M Chitnis1, John S P Yuen, Andrew S Protheroe
1Department of Medical Oncology, Churchill Hospital, Oxford, UK.
Abstract:
Research conducted over the past two decades has shown the importance of the type 1 insulin-like growth factor receptor (IGF1R) in tumorigenesis, metastasis, and resistance to existing forms of cancer therapy. The IGF1R itself has only recently been accepted as a credible treatment target, however, perhaps reflecting the potential problems for drug design posed by normal tissue IGF1R expression, and close homology with the insulin receptor. Currently approximately 12 anti-IGF1R therapeutics are undergoing clinical evaluation, including blocking antibodies and tyrosine kinase inhibitors. This review will summarize the principal signaling pathways activated by IGF1R and the preclinical data that validated this receptor as a treatment target. We will review clinical progress in the testing of IGF1R inhibitory drug candidates, the relative benefits and potential toxicities of coinhibition of the insulin receptor, and the rationale for combining IGF1R blockade with other cancer treatments. An understanding of IGF1R signaling is important because it will guide the incorporation of appropriate molecular markers into clinical trial design. This will be key to the identification of patients most likely to benefit, and so will influence the ability of IGF1R inhibition to make the transition from experimental intervention to clinical therapy.
Insights
The type 1 insulin-like growth factor receptor (IGF1R) is crucial in cancer growth and treatment resistance. Targeting IGF1R shows promise for new cancer therapies, with ongoing clinical trials evaluating its effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The type 1 insulin-like growth factor receptor (IGF1R) plays a significant role in cancer development, metastasis, and therapy resistance.
- IGF1R is a validated therapeutic target, despite challenges in drug design due to normal tissue expression and homology with the insulin receptor.
Purpose of the Study:
- To review the signaling pathways regulated by IGF1R.
- To summarize preclinical data supporting IGF1R as a cancer treatment target.
- To discuss clinical progress, potential toxicities, and combination strategies for IGF1R inhibitors.
Main Methods:
- Review of preclinical research validating IGF1R as a therapeutic target.
- Analysis of ongoing clinical trials for IGF1R inhibitory drug candidates.
- Examination of IGF1R signaling pathways and their role in cancer.
Main Results:
- Approximately 12 anti-IGF1R therapeutics, including antibodies and kinase inhibitors, are in clinical trials.
- Preclinical data strongly support IGF1R as a viable target for cancer therapy.
- Understanding IGF1R signaling is essential for identifying patient populations likely to benefit from treatment.
Conclusions:
- IGF1R inhibition is a promising strategy for cancer treatment.
- Careful patient selection using molecular markers is crucial for successful clinical translation.
- Further research is needed to optimize combination therapies and manage potential toxicities.
More Related Videos
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
01:16TGF - β Signaling Pathway
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22PI3K/mTOR/AKT Signaling Pathway
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle